Literature DB >> 9315400

Attitudes and practice in the management of metastatic colorectal cancer in Britain. Colorectal Cancer Working Party of the UK Medical Research Council.

M T Seymour1, S P Stenning, J Cassidy.   

Abstract

Evidence-based medicine is widely held to be the essential basis of modern therapeutics. The principle of adopting into clinical practice those treatments proved to be of value in randomized trials, or in the systematic review of several trials, in encouraging a welcome proliferation of clinical research and meta-analysis. However, many things affect clinical practice; quantifiable therapeutic benefit is only one of them. Furthermore, in many situations, clear evidence of the best treatment is not available. When discussing ideas for a new trial in advanced colorectal cancer that was launched in 1996, the MRC Colorectal Cancer Working Party carried out a survey of the attitudes and practice of surgeons and oncologists who were treating this condition. This revealed substantial diversity of practice amongst experts in the treatment of this common disease, and prompted us to review the factors that affect clinical practice and to discuss the implications.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9315400     DOI: 10.1016/s0936-6555(97)80010-6

Source DB:  PubMed          Journal:  Clin Oncol (R Coll Radiol)        ISSN: 0936-6555            Impact factor:   4.126


  16 in total

Review 1.  Chemoradiotherapy for colorectal cancer.

Authors:  N Andre; W Schmiegel
Journal:  Gut       Date:  2005-08       Impact factor: 23.059

Review 2.  Palliative chemotherapy for advanced or metastatic colorectal cancer. Colorectal Meta-analysis Collaboration.

Authors: 
Journal:  Cochrane Database Syst Rev       Date:  2000

3.  Palliative chemotherapy for advanced colorectal cancer: systematic review and meta-analysis. Colorectal Cancer Collaborative Group.

Authors:  P C Simmonds
Journal:  BMJ       Date:  2000-09-02

4.  The survival impact of palliative chemotherapy dose modifications on metastatic colon cancer.

Authors:  Mohd Naqib Zainal Abidin; Marhanis Salihah Omar; Farida Islahudin; Noraida Mohamed Shah
Journal:  BMC Cancer       Date:  2022-07-04       Impact factor: 4.638

5.  Prognostic factors of pulmonary metastasectomy for colorectal carcinomas.

Authors:  Fengshi Chen; Nobuharu Hanaoka; Kiyoshi Sato; Takuji Fujinaga; Makoto Sonobe; Tsuyoshi Shoji; Hiroaki Sakai; Ryo Miyahara; Toru Bando; Kenichi Okubo; Toshiki Hirata; Hiroshi Date
Journal:  World J Surg       Date:  2009-03       Impact factor: 3.352

6.  Repeated Liver Resection for Colorectal Liver Metastases: A Comparison with Primary Liver Resections concerning Perioperative and Long-Term Outcome.

Authors:  Kristoffer Jönsson; Gerd Gröndahl; Martin Salö; Bobby Tingstedt; Roland Andersson
Journal:  Gastroenterol Res Pract       Date:  2012-08-29       Impact factor: 2.260

7.  Outcome of microscopic incomplete resection (R1) of colorectal liver metastases in the era of neoadjuvant chemotherapy.

Authors:  Ninos Ayez; Zarina S Lalmahomed; Alexander M M Eggermont; Jan N M Ijzermans; Jeroen de Jonge; Kees van Montfort; Cornelis Verhoef
Journal:  Ann Surg Oncol       Date:  2011-10-18       Impact factor: 5.344

8.  Understanding chemotherapy treatment pathways of advanced colorectal cancer patients to inform an economic evaluation in the United Kingdom.

Authors:  F H Shabaruddin; R A Elliott; J W Valle; W G Newman; K Payne
Journal:  Br J Cancer       Date:  2010-07-27       Impact factor: 7.640

Review 9.  Surgical resection of hepatic metastases from colorectal cancer: a systematic review of published studies.

Authors:  P C Simmonds; J N Primrose; J L Colquitt; O J Garden; G J Poston; M Rees
Journal:  Br J Cancer       Date:  2006-04-10       Impact factor: 7.640

10.  Clinical and economic benefits of irinotecan in combination with 5-fluorouracil and folinic acid as first line treatment of metastatic colorectal cancer.

Authors:  D Cunningham; S Falk; D Jackson
Journal:  Br J Cancer       Date:  2002-06-05       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.